12月22日，先声药业与Ipsen签订独家授权许可协议，Ipsen获SIM0613海外独家开发等权利，先声药业最高可收10.6亿美元款项。2025年，先声药业三款多抗及ADC产品成功授权，跻身BD第一梯队，实现由仿到创转型。2025年上半年，先声药业收入35.85亿元，同比增长15.1%，经调整净利润6.5亿元，同比增长21.1%，源于创新药快速放量，且创新药占比达77.4%，较2024年提升...
Source Link12月22日，先声药业与Ipsen签订独家授权许可协议，Ipsen获SIM0613海外独家开发等权利，先声药业最高可收10.6亿美元款项。2025年，先声药业三款多抗及ADC产品成功授权，跻身BD第一梯队，实现由仿到创转型。2025年上半年，先声药业收入35.85亿元，同比增长15.1%，经调整净利润6.5亿元，同比增长21.1%，源于创新药快速放量，且创新药占比达77.4%，较2024年提升...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.